95 related articles for article (PubMed ID: 9666136)
1. Arachidonylethanolamide (AEA) activation of FOS proto-oncogene protein immunoreactivity in the rat brain.
Patel NA; Moldow RL; Patel JA; Wu G; Chang SL
Brain Res; 1998 Jun; 797(2):225-33. PubMed ID: 9666136
[TBL] [Abstract][Full Text] [Related]
2. Modulation of morphine-induced Fos-immunoreactivity by the cannabinoid receptor antagonist SR 141716.
Singh ME; Verty AN; Price I; McGregor IS; Mallet PE
Neuropharmacology; 2004 Dec; 47(8):1157-69. PubMed ID: 15567425
[TBL] [Abstract][Full Text] [Related]
3. Time course of the effects of different cannabimimetics on prolactin and gonadotrophin secretion: evidence for the presence of CB1 receptors in hypothalamic structures and their involvement in the effects of cannabimimetics.
Fernández-Ruiz JJ; Muñoz RM; Romero J; Villanua MA; Makriyannis A; Ramos JA
Biochem Pharmacol; 1997 Jun; 53(12):1919-27. PubMed ID: 9256167
[TBL] [Abstract][Full Text] [Related]
4. Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain.
Di Marzo V; Breivogel CS; Tao Q; Bridgen DT; Razdan RK; Zimmer AM; Zimmer A; Martin BR
J Neurochem; 2000 Dec; 75(6):2434-44. PubMed ID: 11080195
[TBL] [Abstract][Full Text] [Related]
5. Changes in rat brain cannabinoid binding sites after acute or chronic exposure to their endogenous agonist, anandamide, or to delta 9-tetrahydrocannabinol.
Romero J; García L; Fernández-Ruiz JJ; Cebeira M; Ramos JA
Pharmacol Biochem Behav; 1995 Aug; 51(4):731-7. PubMed ID: 7675852
[TBL] [Abstract][Full Text] [Related]
6. Human platelets and polymorphonuclear leukocytes synthesize oxygenated derivatives of arachidonylethanolamide (anandamide): their affinities for cannabinoid receptors and pathways of inactivation.
Edgemond WS; Hillard CJ; Falck JR; Kearn CS; Campbell WB
Mol Pharmacol; 1998 Jul; 54(1):180-8. PubMed ID: 9658204
[TBL] [Abstract][Full Text] [Related]
7. The endogenous cannabinoid, anandamide, activates the hypothalamo-pituitary-adrenal axis in CB1 cannabinoid receptor knockout mice.
Wenger T; Ledent C; Tramu G
Neuroendocrinology; 2003 Dec; 78(6):294-300. PubMed ID: 14688442
[TBL] [Abstract][Full Text] [Related]
8. Arachidonyl ethanolamide (anandamide) activates the parvocellular part of hypothalamic paraventricular nucleus.
Wenger T; Jamali KA; Juanéda C; Léonardelli J; Tramu G
Biochem Biophys Res Commun; 1997 Aug; 237(3):724-8. PubMed ID: 9299434
[TBL] [Abstract][Full Text] [Related]
9. N-arachidonylethanolamide relaxation of bovine coronary artery is not mediated by CB1 cannabinoid receptor.
Pratt PF; Hillard CJ; Edgemond WS; Campbell WB
Am J Physiol; 1998 Jan; 274(1):H375-81. PubMed ID: 9458889
[TBL] [Abstract][Full Text] [Related]
10. Delta9-tetrahydrocannabinol and endogenous cannabinoid anandamide directly potentiate the function of glycine receptors.
Hejazi N; Zhou C; Oz M; Sun H; Ye JH; Zhang L
Mol Pharmacol; 2006 Mar; 69(3):991-7. PubMed ID: 16332990
[TBL] [Abstract][Full Text] [Related]
11. The distribution of cannabinoid-induced Fos expression in rat brain: differences between the Lewis and Wistar strain.
Arnold JC; Topple AN; Mallet PE; Hunt GE; McGregor IS
Brain Res; 2001 Dec; 921(1-2):240-55. PubMed ID: 11720732
[TBL] [Abstract][Full Text] [Related]
12. Fos induction in selective hypothalamic neuroendocrine and medullary nuclei by intravenous injection of urocortin and corticotropin-releasing factor in rats.
Wang L; Martínez V; Vale W; Taché Y
Brain Res; 2000 Feb; 855(1):47-57. PubMed ID: 10650129
[TBL] [Abstract][Full Text] [Related]
13. Anandamide and sucralose change ΔFosB expression in the reward system.
Salaya-Velazquez NF; López-Muciño LA; Mejía-Chávez S; Sánchez-Aparicio P; Domínguez-Guadarrama AA; Venebra-Muñoz A
Neuroreport; 2020 Feb; 31(3):240-244. PubMed ID: 31923023
[TBL] [Abstract][Full Text] [Related]
14. Induction of Fos-like immunoreactivity by opioids in guinea-pig brain.
Bot G; Chahl LA
Brain Res; 1996 Aug; 731(1-2):45-56. PubMed ID: 8883853
[TBL] [Abstract][Full Text] [Related]
15. Selective effects of the endogenous cannabinoid arachidonylethanolamide (anandamide) on regional cerebral blood flow in the rat.
Stein EA; Fuller SA; Edgemond WS; Campbell WB
Neuropsychopharmacology; 1998 Dec; 19(6):481-91. PubMed ID: 9803424
[TBL] [Abstract][Full Text] [Related]
16. Dynorphin B and spinal analgesia: induction of antinociception by the cannabinoids CP55,940, Delta(9)-THC and anandamide.
Houser SJ; Eads M; Embrey JP; Welch SP
Brain Res; 2000 Feb; 857(1-2):337-42. PubMed ID: 10700588
[TBL] [Abstract][Full Text] [Related]
17. Biochemistry and pharmacology of arachidonylethanolamide, a putative endogenous cannabinoid.
Hillard CJ; Campbell WB
J Lipid Res; 1997 Dec; 38(12):2383-98. PubMed ID: 9458263
[TBL] [Abstract][Full Text] [Related]
18. Modulation of trigeminal sensory neuron activity by the dual cannabinoid-vanilloid agonists anandamide, N-arachidonoyl-dopamine and arachidonyl-2-chloroethylamide.
Price TJ; Patwardhan A; Akopian AN; Hargreaves KM; Flores CM
Br J Pharmacol; 2004 Apr; 141(7):1118-30. PubMed ID: 15006899
[TBL] [Abstract][Full Text] [Related]
19. Physiological and behavioural effects of the endogenous cannabinoid, arachidonylethanolamide (anandamide), in the rat.
Stein EA; Fuller SA; Edgemond WS; Campbell WB
Br J Pharmacol; 1996 Sep; 119(1):107-14. PubMed ID: 8872363
[TBL] [Abstract][Full Text] [Related]
20. Isotope dilution mass spectrometric measurements indicate that arachidonylethanolamide, the proposed endogenous ligand of the cannabinoid receptor, accumulates in rat brain tissue post mortem but is contained at low levels in or is absent from fresh tissue.
Kempe K; Hsu FF; Bohrer A; Turk J
J Biol Chem; 1996 Jul; 271(29):17287-95. PubMed ID: 8663381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
